CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with...
NEW YORK , April 1, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO) concerning...
NEW YORK , March 31, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:
Company has already submitted proposed confirmatory trial for FDA review, as required under accelerated approval pathway Company plans to submit mitapivat sNDA in sickle cell disease in the coming...
NEW YORK , March 25, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...
NEW YORK , March 18, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...
NEW YORK , March 17, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:
NEW YORK , March 11, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...
NEW YORK , March 10, 2026 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Agios Pharmaceuticals, Inc.:
NEW YORK , March 4, 2026 /PRNewswire/ -- Levi & Korsinsky notifies investors that it has commenced an investigation of Agios Pharmaceuticals, Inc. ("Agios Pharmaceuticals, Inc.") (NASDAQ: AGIO)...